Abacus Global Management, a $740 million special purpose acquisition company (SPAC) trading under the ticker ABL, is facing allegations of accounting irregularities related to its life settlements business. A recent report accused the company of manufacturing fake revenue by systematically underestimating life expectancy assumptions, which impacts the timing of expected payouts. Following the release of this report, Abacus Life's stock price declined by approximately 23%. The report also raised concerns about the company's relationship with Lapetus and its discount rate assumptions. In response to these allegations, securities fraud investigations into Abacus Global Management have been announced, with law firms such as Gibbs Mura and Glancy Prongay & Murray LLP urging investors who suffered losses to come forward. These developments come amid broader securities fraud investigations and investor alerts involving other companies, including Organon & Co., Red Cat Holdings, Neogen Corporation, Reckitt Benckiser Group PLC, and Flowserve Corporation.